FDA Approves Wider Use Visudyne

Article

QLT, Inc. and Ciba Vision Corporation have been given priority-review status from the Food and Drug Administration (FDA) for their application to expand therapy involving their blindness drug Visudyne to treatment of a range of eye diseases. Among other things, the companies are seeking permission to use Visudyne to treat certain conditions that can cause blindness in younger people. Currently, the two companies have US marketing approval for its use to treat only certain forms of age-related macular degeneration, the leading cause of blindness in people over 50 years old. For more information, visit www.fda.org.

Recent Videos
Anthony Bondon CRCST, CHL, BSM, AAS, SME, LSSYB
Deannard Esnard, CRCST, CIS, CER, CHL, CFER, CQUIA
Kevin Bush, Jr, DHSc, EdD, MSHA, MA, MS, FACHE
Vatsala Rangachar Srinivasa, MPH
Sarah Vinson, MBA, CRCST
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
APIC 2025 President Carol McLay, DrPH, MPH, RN, CIC FAPIC   (Image credit: APIC)
Related Content